Cabozantinib in genitourinary malignancies

Tian Zhang, Se Eun Park, Cierra Hong, Daniel J. George

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)755-765
Number of pages11
JournalFuture Oncology
Volume13
Issue number8
DOIs
StatePublished - Apr 2017
Externally publishedYes

Keywords

  • cabozantinib
  • genitourinary malignancies
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cabozantinib in genitourinary malignancies'. Together they form a unique fingerprint.

Cite this